TY - JOUR
T1 - Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality
T2 - A survey on behalf of the ALWP of the EBMT
AU - Chevallier, P.
AU - Labopin, M.
AU - Nagler, A.
AU - Ljungman, P.
AU - Verdonck, L. F.
AU - Volin, L.
AU - Zander, A. R.
AU - Finke, J.
AU - Socie, G.
AU - Cordonnier, C.
AU - Harousseau, J. L.
AU - Mohty, M.
AU - Rocha, V.
PY - 2009
Y1 - 2009
N2 - The aim of this multicenter retrospective analysis was to carry out a survey of overall outcomes after allo-hematopoietic SCT of AML patients harboring trisomy 8 (+8) as the sole chromosomal abnormality or associated with other abnormalities. We have identified 182 de novo AML patients who underwent allo-hematopoietic SCT between 1990 and 2007 exhibiting isolated +8 (n = 136) or +8 (n = 46) associated with other favorable (n = 8), intermediate (n = 30), high-risk (n = 7) or unknown (n = 1) cytogenetic abnormalities reported to the European Group of Blood and Marrow Transplantation (EBMT). With a median follow-up of 48 months, 5-year non-relapse mortality, relapse rate, leukemia-free survival and OS were 25, 30, 45 and 47%, respectively. In a multivariate analysis, leukemia-free survival rate was improved when patients were female and transplanted in CR with an HLA-identical sibling donor. Five-year leukemia-free survival was 41, 88, 57 and 21% in patients bearing isolated +8 or +8 and other cytogenetic abnormalities of good, intermediate or poor-risk, respectively. Our retrospective data show that allo-hematopoietic SCT is an effective treatment for AML patients harboring +8. The accompanying cytogenetic abnormality to +8 seems to influence outcomes of these patients.
AB - The aim of this multicenter retrospective analysis was to carry out a survey of overall outcomes after allo-hematopoietic SCT of AML patients harboring trisomy 8 (+8) as the sole chromosomal abnormality or associated with other abnormalities. We have identified 182 de novo AML patients who underwent allo-hematopoietic SCT between 1990 and 2007 exhibiting isolated +8 (n = 136) or +8 (n = 46) associated with other favorable (n = 8), intermediate (n = 30), high-risk (n = 7) or unknown (n = 1) cytogenetic abnormalities reported to the European Group of Blood and Marrow Transplantation (EBMT). With a median follow-up of 48 months, 5-year non-relapse mortality, relapse rate, leukemia-free survival and OS were 25, 30, 45 and 47%, respectively. In a multivariate analysis, leukemia-free survival rate was improved when patients were female and transplanted in CR with an HLA-identical sibling donor. Five-year leukemia-free survival was 41, 88, 57 and 21% in patients bearing isolated +8 or +8 and other cytogenetic abnormalities of good, intermediate or poor-risk, respectively. Our retrospective data show that allo-hematopoietic SCT is an effective treatment for AML patients harboring +8. The accompanying cytogenetic abnormality to +8 seems to influence outcomes of these patients.
UR - http://www.scopus.com/inward/record.url?scp=70749116930&partnerID=8YFLogxK
U2 - 10.1038/bmt.2009.68
DO - 10.1038/bmt.2009.68
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 19349953
AN - SCOPUS:70749116930
SN - 0268-3369
VL - 44
SP - 589
EP - 594
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 9
ER -
